Value of the TTM risk score for early prognostication of comatose patients after out-of-hospital cardiac arrest in a Swiss university hospital.


Journal

Swiss medical weekly
ISSN: 1424-3997
Titre abrégé: Swiss Med Wkly
Pays: Switzerland
ID NLM: 100970884

Informations de publication

Date de publication:
07 Sep 2020
Historique:
entrez: 13 9 2020
pubmed: 14 9 2020
medline: 19 8 2021
Statut: epublish

Résumé

Comatose patients admitted to the intensive care unit (ICU) after out-of-hospital cardiac arrest frequently die after withdrawal of life support. Guidelines recommend scheduling prognostication no sooner than 96 hours after cardiac arrest, and strict withdrawal criteria leave many patients waiting for improvement for days without ever reaching a favourable outcome. In clinical practice, physicians are frequently confronted with vague living wills expressed by next of kin or an imprecise advance care directive soon after cardiac arrest. Often a decision to admit a patient to an ICU or limiting ICU treatment in terms of time or intensity is made early, based on the patient’s preferences. The Target Temperature Management (TTM) risk score is an imperfect measure that predicts outcome early, at the time of ICU admission. It was developed on a data set of 939 patients included in the TTM Trial, a study in which unconscious patients after cardiac arrest were randomised into two temperature management arms. Patient selection in that trial might impede generalisability. We aimed to validate the TTM risk score with 100 consecutive patients treated in our ICU. Although we had different survival rates, reflecting a different patient population, we were able to confirm the score’s albeit imperfect ability to predict outcome early after cardiac arrest. The suggested cut-off values of 10 and 16 can be used as a basis for discussion with the family; in particular, a risk score value below 10 predicts a favourable outcome and might guide early discussion. As in the original study, the outcome of an individual patient cannot be predicted. (ClinicalTrials.gov Identifier: NCT02722460).

Identifiants

pubmed: 32920792
doi: 10.4414/smw.2020.20344
pii: Swiss Med Wkly. 2020;150:w20344
doi:
pii:

Banques de données

ClinicalTrials.gov
['NCT02722460']

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

w20344

Auteurs

Emmanuel Kägi (E)

Department of Intensive Care Medicine, Bern University Hospital, Inselspital, University of Bern, Switzerland.

Anja Weck (A)

Department of Intensive Care Medicine, Bern University Hospital, Inselspital, University of Bern, Switzerland / Department of Intensive Care Medicine, Hospital Region Biel/Bienne, Switzerland.

Manuela Iten (M)

Department of Intensive Care Medicine, Bern University Hospital, Inselspital, University of Bern, Switzerland.

Anja Levis (A)

Department of Intensive Care Medicine, Bern University Hospital, Inselspital, University of Bern, Switzerland / Department of Anaesthesiology and Pain Medicine, Bern University Hospital, Inselspital, University of Bern, Switzerland.

Matthias Haenggi (M)

Department of Intensive Care Medicine, Bern University Hospital, Inselspital, University of Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH